SciELO - Scientific Electronic Library Online

 
vol.32 issue4Susceptibility of Helicobacter Pylori to Antibiotics: a Study of Prevalence in Patients with Dyspepsia in Quito, EcuadorDisease Burden of Gastric Cancer in Disability-Adjusted Life Years in Colombia author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista colombiana de Gastroenterología

Print version ISSN 0120-9957

Abstract

MARQUEZ,, Juan Ricardo  and  GOMOLLON, Fernando. The Role of Biosimilars in Inflammatory Bowel Disease: A Reality in our Country. Rev Col Gastroenterol [online]. 2017, vol.32, n.4, pp.311-325. ISSN 0120-9957.  https://doi.org/10.22516/25007440.174.

The term Inflammatory Bowel Disease (IBD) is used to identify several entities, the two most important of which are Idiopathic Ulcerative Colitis (IUC) and Crohn’s Disease (EC). Both are multifactorial in origin, are chronic and recurrent, are characterized by inflammation, have varying degrees of severity, and potentially involve other organs.

In the last decade there has been renewed interest in these entities due to growing incidence and to the development of drugs called biologicals. For the first time, these drugs have changed the natural history of these diseases. They are produced or derived from living organisms and represent the fastest growing sector in the global pharmaceutical industry. Due to commercial interest, products similar but not identical to the original products have been developed and submitted to regulatory authorities.

The European Medicines Agency has approved the first biosimilar for infliximab for all indications for which it has been approved. These include moderate to severe ulcerative colitis (UC) at all ages, moderate to severe Crohn’s disease (CD) at all ages, fistulizing Crohn’s disease, Psoriasic arthritis, Psoriasis, Ankylosing Spondylitis, and Rheumatoid Arthritis 1.

In this review, we define what these products are, as well as some concepts coined for their usage including extrapolation, substitution and interchangeability. We also make a historical review of their development, current indications, the positions of various scientific associations with respect to them, and - most importantly - provide real-life data regarding their effectiveness, safety and costs in countries where they have been used.

Keywords : Biosimilar; biological agents; anti TNF; extrapolation; substitution and interchangeability.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )